Posted by Michael Wonder on 13 Mar 2022
Alzheimer's patient groups pressure U.S. to pay for Biogen drug
13 March 2022 - Patient groups are mounting a public pressure campaign aimed at persuading the U.S. Government to loosen proposed restrictions on new Alzheimer’s treatments, spending millions of dollars on television and local advertisements that began running during the Sunday morning political shows.
The unusual ad campaign comes after a high-profile disagreement between government health agencies over who should have access to Biogen’s Aduhelm, the first treatment for the mind wasting disease to be approved in 20 years.
